PMID- 37534324
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230804
IS  - 2405-5808 (Electronic)
IS  - 2405-5808 (Linking)
VI  - 35
DP  - 2023 Sep
TI  - Umbilical mesenchymal stem cell-derived exosomes promote spinal cord functional 
      recovery through the miR-146b/TLR4 -mediated NF-kappaB p65 signaling pathway in rats.
PG  - 101497
LID - 10.1016/j.bbrep.2023.101497 [doi]
LID - 101497
AB  - Spinal cord injury (SCI) is an incurable central nervous system impairment that 
      lack of efficient treatment. Exosomes derived from mesenchymal stem cells (MSCs) 
      are widely applied in disease treatment. This work aimed to determine the 
      promising therapeutic effects of MSC-derived exosomal miRNA146b on SCI. A rat 
      spinal cord injury (SCI) model and lipopolysaccharide (LPS)-induced PC12 cell 
      model were established. Exosomes were extracted from human umbilical cord 
      mesenchymal stem cells (hUCMSCs). The identification of exosomes was performed by 
      using transmission electronic microscope (TEM) and nanoparticle tracking analysis 
      (NTA). Hematoxylin and eosin (HE) staining and TUNEL assay were performed to 
      assess tissue damage and apoptosis, respectively. ELISA was performed to detect 
      levels of inflammatory cytokines. Cell viability was checked by cell counting kit 
      8 (CCK-8). Gene expression and protein levels were detected by qPCR and western 
      blotting assay. The interaction between miR-146 b and Toll-like receptor 4 (TLR4) 
      was assessed by luciferase reporter gene assay. The hUCMSC-derived exosomes could 
      notably alleviate the spinal cord injury and cell apoptosis. The exosomal 
      miR-146 b treatment suppressed the release of IL-1 beta, IL-6, and TNFalpha. The 
      miR-146 b suppressed the expression of TLR4, directly interact with the 
      3'-untranslated region (3'UTR) of TLR4, and inactivated the nuclear factor kappaB 
      (NF-kappaB) signaling. The hUCMSCs-derived exosomal miR-146 b protects neurons from 
      spinal cord injury through targeting the TLR4 and inactivating the NF-kappaB 
      signaling. Our findings supported the application of hUCMSCs-derived exosomal 
      miR-146 b for the protection of SCI.
CI  - (c) 2023 Everunion Biotechnology Co., LTD. Tianjin.
FAU - Wang, Xiujuan
AU  - Wang X
AD  - Technology Department, Everunion Biotechnology Co. LTD, Tianjin, China.
FAU - Yang, Ying
AU  - Yang Y
AD  - Technology Department, Everunion Biotechnology Co. LTD, Tianjin, China.
FAU - Li, Wei
AU  - Li W
AD  - Technology Department, Everunion Biotechnology Co. LTD, Tianjin, China.
FAU - Hao, MingYuan
AU  - Hao M
AD  - Technology Department, Everunion Biotechnology Co. LTD, Tianjin, China.
FAU - Xu, YongSheng
AU  - Xu Y
AD  - Technology Department, Everunion Biotechnology Co. LTD, Tianjin, China.
LA  - eng
PT  - Journal Article
DEP - 20230720
PL  - Netherlands
TA  - Biochem Biophys Rep
JT  - Biochemistry and biophysics reports
JID - 101660999
PMC - PMC10393557
OTO - NOTNLM
OT  - Exosomes
OT  - Mesenchymal stem cell
OT  - Spinal cord injury
OT  - Toll-like receptor 4
OT  - miR-146b
COIS- There are no conflicts of interest.
EDAT- 2023/08/03 06:42
MHDA- 2023/08/03 06:43
PMCR- 2023/07/20
CRDT- 2023/08/03 04:29
PHST- 2023/01/09 00:00 [received]
PHST- 2023/06/01 00:00 [revised]
PHST- 2023/06/05 00:00 [accepted]
PHST- 2023/08/03 06:43 [medline]
PHST- 2023/08/03 06:42 [pubmed]
PHST- 2023/08/03 04:29 [entrez]
PHST- 2023/07/20 00:00 [pmc-release]
AID - S2405-5808(23)00078-X [pii]
AID - 101497 [pii]
AID - 10.1016/j.bbrep.2023.101497 [doi]
PST - epublish
SO  - Biochem Biophys Rep. 2023 Jul 20;35:101497. doi: 10.1016/j.bbrep.2023.101497. 
      eCollection 2023 Sep.